Apr 29 |
Atossa Therapeutics announces expanded research agreement with Weill Cornell Medicine
|
Apr 29 |
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV
|
Apr 29 |
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
|
Apr 15 |
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
|
Apr 11 |
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
|
Apr 9 |
Atossa stock climbs 11% on breast cancer drug data
|
Apr 9 |
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
|
Apr 5 |
ATOS, SMR and EIGR are among pre market gainers
|
Apr 1 |
Atossa Therapeutics GAAP EPS of -$0.24 in-line
|
Apr 1 |
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
|